Tocilizumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | IL-6 receptor |
| Clinical data | |
| ATC code | |
| Legal status | |
| Legal status | |
Tocilizumab (under development by Roche and Chugai under the trade name Actemra) is a humanized monoclonal antibody against IL-6R (interleukin-6 receptor) used as an immunosuppressive drug.
As of 2008, it is currently under regulatory review by the United States Food and Drug Administration (US FDA) and the European Medicines Agency (EMA).
It has been proposed for use in Castleman's disease.[2]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ Matsuyama M, Suzuki T, Tsuboi H; et al. (2007). "Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease". Intern. Med. 46 (11): 771–4. PMID 17541233.
{{cite journal}}: Explicit use of et al. in:|author=(help)CS1 maint: multiple names: authors list (link)
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |